Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Cabaletta Bio Inc(CABA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CABA
09/24/2026: CABA (1-star) is currently NOT-A-BUY. Pass it for now.
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies intended to address B cell-mediated autoimmune diseases. Its primary value proposition lies in the potential of its CABA platform to provide targeted, potentially curative treatments for complex conditions. While the company has a promising pipeline, most notably CABA-201, it remains a pre-revenue entity facing high financial and clinical execution risks. Investors should monitor clinical data readouts and the company's ability to maintain its cash runway through future development milestones. This stock is best suited for growth-oriented investors with a high tolerance for the volatility typical of clinical-stage biotechnology equities.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-growth potential via clinical development, but carries the inherent risks of a pre-revenue biotech firm. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find the stock attractive during positive clinical data news cycles or potential partnership announcements. |
| Value investor | Weak fit | The company lacks earnings, cash flow, or a long-term revenue base, making it unsuitable for traditional value-based strategies. |
| Dividend investor | Weak fit | Cabaletta Bio is a clinical-stage biotech and does not pay dividends. |
| Low-risk investor | Weak fit | The high volatility and binary nature of clinical biotech risks make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to significant price swings based on clinical trial updates and biotech market sentiment. |
| Valuation risk | High | Valuation is highly speculative, relying on future probabilities of regulatory success rather than current earnings. |
| Competition risk (Large Pharma/Biotech) | Medium / high | Large competitors with more resources could develop superior therapies or gain market share more effectively. |
| Business quality | Medium | While the platform technology is innovative, the lack of commercialized products limits the quality assessment to clinical potential. |
| Dividend income | Low / none | The company reinvests all capital into R&D and provides no income. |
| Execution risk | High | The company must successfully navigate complex clinical trials and regulatory approval processes to survive and grow. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -82.36% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/24/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 376.39M USD | Price to earnings Ratio - | 1Y Target Price 13.25 |
Price to earnings Ratio - | 1Y Target Price 13.25 | ||
Volume (30-day avg) 5.7M shares | Beta 3.26 | 52 Weeks Range 2.00 - 4.23 | Updated Date 09/24/2026 |
52 Weeks Range 2.00 - 4.23 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.22 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development / R&D | The business relies on capital raises to fund research for CABA-201 and other pipeline assets. | The company is currently not generating revenue and relies on selling stock to fund its research projects. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 223.63M | Price to Sales(TTM) - |
Enterprise Value 223.63M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.44 | Shares Outstanding 169.55M | Shares Floating 141.48M |
Shares Outstanding 169.55M | Shares Floating 141.48M | ||
Percent Insiders 0.97 | Percent Institutions 94.08 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Cabaletta Bio Inc
Exchange NASDAQ | Headquarters Philadelphia, PA, United States | ||
IPO Launch date 2019-10-25 | Co-Founder, Chairman, CEO & President Dr. Steven A. Nichtberger M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 154 | Website https://www.cabalettabio.com |
Full time employees 154 | Website https://www.cabalettabio.com | ||
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.